Owens P C, Gill P G, De Young N J, Weger M A, Knowles S E, Moyse K J
Department of Surgery, University of Adelaide, Australia.
Biochem Biophys Res Commun. 1993 Jun 15;193(2):467-73. doi: 10.1006/bbrc.1993.1647.
We examined the effects of estradiol and progesterone agonist, promegestone (R5020), on secretion of insulin-like growth factors (IGF) and binding proteins (IGFBPs) by T-47D human breast cancer cells cultured in a serum-free defined medium. Estrogen, IGF-I and IGF-II promoted and R5020 inhibited growth under these conditions. Cells secreted IGFs and four IGFBPs. The amounts of all IGFBPs in cell-conditioned media were increased by estradiol and reduced by R5020, which also abolished the stimulatory effect of estradiol on IGFBPs without inducing an IGFBP protease. Therefore estrogen and progesterone may alter growth of breast cancers by regulating tumour secretion of IGFBPs and hence change carcinoma responsiveness to IGFs.
我们研究了雌二醇和孕激素激动剂普罗美孕酮（R5020）对在无血清限定培养基中培养的T-47D人乳腺癌细胞分泌胰岛素样生长因子（IGF）和结合蛋白（IGFBP）的影响。在这些条件下，雌激素、IGF-I和IGF-II促进细胞生长，而R5020抑制细胞生长。细胞分泌IGF和四种IGFBP。雌二醇增加了细胞条件培养基中所有IGFBP的含量，而R5020则使其降低，R5020还消除了雌二醇对IGFBP的刺激作用，且未诱导IGFBP蛋白酶的产生。因此，雌激素和孕激素可能通过调节肿瘤IGFBP的分泌来改变乳腺癌的生长，从而改变癌细胞对IGF的反应性。
